Application in general practice of treatment guidelines for patients with dyslipidaemia: The RESPECT study

被引:10
|
作者
Cacoub, Patrice [1 ]
Gousse, Elisabeth Tocque-Le [2 ]
Fabry, Caroline [2 ]
Hermant, Sophie [3 ]
Petzold, Loic [4 ]
机构
[1] Univ Paris 06, Grp Hosp La Pitie Salpetriere, AP HP, Serv Med Interne, F-75013 Paris, France
[2] Lab Astra Zeneca, F-92844 Paris, France
[3] Excip, F-14000 Caen, France
[4] Axonal, F-92024 Nanterre, France
关键词
Dyslipidemia; Cardiovascular disease; Cholesterol; Risk factor; General practice;
D O I
10.1016/j.acvd.2008.09.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background.- Screening for and management of dyslipidaemia are crucial in primary and secondary prevention of cardiovascular disease. The impact on general practitioners (GP) of the 2005 French guidelines for hypercholesterolaemia has not been evaluated. Aims.- To compare GP's estimation of cardiovascular risk with that from a theoretical calculation; to analyse the consequences of cardiovascular-risk estimation on the threshold of therapeutic intervention and the target tow-density lipoprotein cholesterol (LDL-C) concentration; and to analyse patients' awareness of their hypercholesterolaemia. Methods.- The RESPECT study was a transverse, multicentre, observational survey conducted between March 2006 and February 2007 by 1797 GP in France. Inclusion criteria were adults with primary hypercholesterolaemia who had not taken lipid-lowering drugs within the previous 6 months. Results.- Of the 5627 patients included (60.9% men; mean age standard deviation 58.2 +/- 11.0 years; body mass index 27.2 +/- 4.1 kg/m(2); mean total cholesterol 2.68 +/- 0.37 g/L; LDL-C 1.79 +/- 0.35 g/L), 1963 (36.2%) had at least three cardiovascular risk factors. GP identified a high cardiovascular risk level in 40.8%, moderate risk in 45.8% and tow risk in 13.4% of patients. These compared with calculated rates of 48, 23 and 29%, respectively (kappa concordance 59.4%). For most patients (98.2%), GP defined the therapeutic target based on LDL-C concentration. The target LDL-C was significantly different when cardiovascular risk was estimated by GP versus that calculated theoretically. The higher the estimated risk level, the greater the rate of introduction of lipid-lowering drugs and the shorter the time to the next GP visit. Most patients considered themselves to be well or rather well informed about their cholesterol concentration (91.3%), the causes (64.3%) and consequences of chotesterol-induced diseases (83.7%), and the difference between 'good' and 'bad' cholesterol (57%). Most (81.5%) patients were aware of the benefits of lipid-lowering drugs on cardiovascular disease prevention; 95.8% considered adequate diet and compliance with pharmacological treatment to be very important. Conclusion.- Recent French guidelines for hypercholesterolaemia are used widely by GP in practice. They enable correct assessment of overall cardiovascular risk level, have an impact on the therapeutic threshold of intervention by physicians and improve patients' awareness of the relevance of cholesterol concentration. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:715 / 721
页数:7
相关论文
共 50 条
  • [11] Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM
    Jeck, T
    Riesen, WF
    Keller, U
    DIABETIC MEDICINE, 1997, 14 (07) : 564 - 570
  • [12] AUSDRISK Application in general practice
    Wong, Kam Cheong
    Brown, Anthony M.
    Li, Stephen C. H.
    AUSTRALIAN FAMILY PHYSICIAN, 2011, 40 (07) : 524 - 526
  • [13] Cultural respect in general practice: a cluster randomised controlled trial
    Hickey, Sophie
    West, Roianne
    MEDICAL JOURNAL OF AUSTRALIA, 2019, 211 (01) : 43 - +
  • [14] Cultural respect in general practice: a cluster randomised controlled trial
    Liaw, Siaw-Teng
    Wade, Vicki
    Furler, John S.
    Hasan, Iqbal
    Lau, Phyllis
    Kelaher, Margaret
    Xuan, Wei
    Harris, Mark F.
    MEDICAL JOURNAL OF AUSTRALIA, 2019, 210 (06) : 263 - 268
  • [15] New Zealand guidelines for the management of dyslipidaemia: Implications for treatment in an urban New Zealand population
    North, D
    LayYee, R
    Jackson, R
    NEW ZEALAND MEDICAL JOURNAL, 1996, 109 (1020) : 134 - 137
  • [16] Treatment of hypertension in Finnish general practice seems unsatisfactory despite evidence-based guidelines
    Varis, Juha
    Savola, Heljae
    Vesalainen, Risto
    Kantola, Ilkka
    BLOOD PRESSURE, 2009, 18 (1-2) : 62 - 67
  • [17] CITALOPRAM AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL-PRACTICE - A NORDIC MULTICENTER CLINICAL-STUDY
    ROSENBERG, C
    DAMSBO, N
    FUGLUM, E
    JACOBSEN, LV
    HORSGARD, S
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1994, 9 : 41 - 48
  • [18] Experiences of using the Recommended Summary Plan for Emergency Care and Treatment (ReSPECT) in English general practice: a qualitative study among key primary health and social care professionals, patients, and their relatives
    Slowther, Anne-Marie
    Bernstein, Celia Janine
    Huxley, Caroline
    Harlock, Jenny
    Eli, Karin
    Mann, Claire
    Spencer, Rachel
    Dale, Jeremy
    Gill, Paramjit
    Blanchard, Hazel
    Underwood, Martin
    Griffiths, Frances
    BRITISH JOURNAL OF GENERAL PRACTICE, 2025, 75 (751): : e143 - e152
  • [19] COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines?
    Savran, Osman
    Godtfredsen, Nina
    Sorensen, Torben
    Jensen, Christian
    Ulrik, Charlotte Suppli
    CHRONIC RESPIRATORY DISEASE, 2019, 16
  • [20] Statin treatment and LDL target value achievement in Swiss general practice - a retrospective observational study
    Yael, Rachamin
    Rahel, Meier
    Thomas, Rosemann
    Stefan, Langenegger
    Stefan, Markun
    SWISS MEDICAL WEEKLY, 2020, 150